Moderna, Inc.
718 articles with Moderna, Inc.
-
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
-
The Cambridge, Massachusetts-based company has developed an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
-
IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.
-
Researchers from Harvard University and the U.S. Department of Veterans Affairs (VA) found that the Moderna mRNA vaccine was slightly better than the Pfizer-BioNTech vaccine.
-
Research continues to reveal how COVID-19 affects different people with different health issues, both short-term and long-term.
-
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
12/1/2021
Moderna, Inc. (Nasdaq: MRNA), today announced a revised supply agreement with the UK government for up to 60 million doses of Moderna’s COVID-19 vaccine, which may include authorized booster vaccine candidates, with up to 29 million doses expected to be delivered in 2022 and up to 31 million doses expected to be delivered in 2023.
-
It may take two to four weeks before experts have enough data to know whether Omicron is a bigger threat than Delta. Much of what is known is based on lab tests and models of the virus’ spike protein mutations.
-
Omicron Update: CDC, Biden Advise Urgency
11/30/2021
The CDC has shifted its recommendation on adults getting a booster COVID-19 vaccine to now include everyone ages 18 years and older. -
The whole world is watching the news about Omicron, but it’s obvious that it will be a week or two before enough is known about the new variant of concern.
-
Welcome to the New Reality of Omicron
11/29/2021
The World Health Organization officially declared omicron – aka. B.1.1.529 – a variant of concern (VOC) on Friday. -
Omicron has caused the U.S. to install travel bans against several South African countries while vaccine makers rush to test their vaccines against it. For that news and more, continue reading.
-
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
11/26/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced updates to its strategy to address SARS-CoV-2 variants of concern, given the emergence of the B.1.1.529 variant.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Moderna to Present at Upcoming Investor Conferences in December 2021
11/22/2021
Moderna, Inc. today announced its participation in the following upcoming virtual investor conferences: NASDAQ 45th Investor Conference on Wednesday, December 1st at 9:30 a.m. ET.
-
The recommendation comes after a thorough evaluation of both products' effectiveness and safety profiles, presented at the Advisory Committee on Immunization Practices last week.
-
Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters
11/19/2021
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine.
-
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
11/19/2021
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older.
-
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
-
The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.
-
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine
11/18/2021
Moderna, Inc. today announced the first participant has been dosed in the Phase 2/3 study of mRNA-1345, the Company’s Respiratory Syncytial Virus (RSV) vaccine candidate.